m123456, IMO Takeda co-operation takes much more time than just over 1y. It is an animal study or several of them, I suppose and when we get to phase 2 with PBT434 it is a very good thing to know more about the gastrointestinal dysfunction in PD (or MSA) and if PBT434 will help these symptoms and how. The paper below tells more about these gastro problems. PD is a system disease and we can talk today about gastroparesis but understanding of it is still not perfect.
During the past 25 years, there has been an explosion of information regarding the occurrence of gastrointestinal dysfunction in Parkinson's disease. In this review, the clinical features of gastrointestinal dysfunction in Parkinson's disease will be described and information regarding the potential role of the enteric nervous system and the gut microbiome in the genesis of Parkinson's disease will be addressed.
RECENT FINDINGS:
Recognition is growing regarding the role that gastroparesis and small intestinal dysfunction may play in Parkinson's disease, especially with regard to erratic responses to anti-Parkinson medication. The presence of enteric nervous system involvement in Parkinson's disease is now well established, but whether the enteric nervous system is the starting point for Parkinson's disease pathology remains a source of debate. The potential role of the gut microbiome also is beginning to emerge. Gastrointestinal dysfunction is a prominent nonmotor feature of Parkinson's disease and dysfunction can be found along the entire length of the gastrointestinal tract. The enteric nervous system is clearly involved in Parkinson's disease. Whether it is the initial source of pathology is still a source of controversy. There also is growing recognition of the role that the gut microbiome may play in Parkinson's disease, but much more research is needed to fully assess this aspect of the disorder.
PBT Price at posting:
4.4¢ Sentiment: None Disclosure: Held
